Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.38 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloromethane SCHEMBL11360800 | 0.89 | CYP3A4 (0.58) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL26559 | 0.89 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL29177519 | 0.89 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL15389152 | 0.89 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL27690619 | 0.88 | CYP3A4 (0.52) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL27465608 | 0.87 | LPAR3 (0.39) | CYP3A4LPAR3LPAR2LPAR1 | |
| Methane SCHEMBL11359992 | 0.87 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL11677508 | 0.87 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL4631198 | 0.87 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| Ammonia Solution, Strong SCHEMBL5519376 | 0.87 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-216396344-U | Di-tert-butyl chloromethyl phosphate production is with taking stirring inside lining to prepare cauldron | 武汉康贝德生物科技有限公司 | 2022-04-29 | — | — | CN | claimed |
| JP-4734318-B2 | — | — | 2011-07-27 | — | — | JP | claimed |
| US-7745625-B2 | Prodrugs of piperazine and substituted piperidine antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | claimed |
| EP-1725569-B1 | PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2008-01-23 | — | — | EP | claimed |
| EP-1725569-A1 | PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2006-11-29 | — | — | EP | claimed |
| WO-2005090367-A1 | PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050209246-A1 | Prodrugs of piperazine and substituted piperidine antiviral agents | SALZUFER HOLDING INC., AS ADMINISTRATIVE AGENT | 2005-09-22 | — | — | US | claimed |
| WO-2023196614-A1 | METHODS AND COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | AXONIS THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023055686-A1 | LPXC INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-4126863-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | Vertex Pharmaceuticals Incorporated (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022206512-A1 | 5-BENZYLIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川大学华西医院 | 2022-10-06 | — | — | WO | disclosed |
| EP-4003340-A2 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | Angion Biomedica Corp. (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021203025-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2010065893-A1 | RAF INHIBITORS AND THEIR USES | ARQULE, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| EP-2121029-A2 | PRODRUGS AND METHODS OF MAKING AND USING THE SAME | Neurogesx, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008070149-A2 | PRODRUGS AND METHODS OF MAKING AND USING THE SAME | NEUROGESX, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| EP-1891070-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1856135-A1 | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006138376-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006078846-A1 | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209246-A1 | Prodrugs of piperazine and substituted piperidine antiviral agents | ZC3HAV1L, CCR5, CCRL2 | CYP3A4 1230/4885LPAR3 322/4885LPAR2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.